RNA Formulation Videos
-
Q&A On LNP Cell-Specific Delivery
11/28/2022
In this video, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery for Strand Therapeutics, outline several examples of foundational research that could provide insights into how we attain more specific cellular uptake of LNPs.
-
mRNA's Future Beyond The COVID Vaccines
11/28/2022
In this video, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, unpack which learnings can be adapted from ASO-LNPs to mRNA/LNPs and from mRNA vaccines to mRNA therapeutics. They also touch upon which learnings cannot be neatly carried over from these previous success stories.
-
mRNA LNP Scale Up For GMP Vaccine Production
4/14/2022
Explore an overview of the development and scale-up activities needed to develop high quality lipid nanoparticles and progress this saRNA vaccine to the clinic.
-
Molecular And Colloidal Ionization Properties Of Lipid Nanoparticle mRNA Vaccines
4/13/2022
Dr. Michael Buschmann, George Mason University, presents an overview of molecular and colloidal ionization properties of lipid nanoparticle mRNA vaccines.
-
Scale-Up And Production Of Key Lipids Used In mRNA Delivery Systems
2/13/2025
Discover key strategies for overcoming challenges in the industrial-scale production of ionizable and PEG lipids to optimize mRNA vaccine formulation and address critical manufacturing requirements.
-
RNA-LNP Manufacturing Technology Delivering Transformative Medicines
10/13/2022
NxGen™ microfluidic technology enables controlled and precise assembly of high-quality, uniform LNPs, ensuring reproducible scale-up of RNA-LNPs while maximizing drug loading and particle quality.
-
Insights And Strategies For GMP Manufacturing Of RNA-Lipid Nanoparticles
4/25/2024
The emergence of RNA-encapsulated-lipid nanoparticles has introduced a seismic shift in biopharma innovation. But how will the industry adapt to diversifying applications and scales going forward?
-
R&D & CMC Priorities For LNPs Beyond Cell-Specific Delivery
12/4/2024
It goes without saying that achieving cell-specific delivery is the most often discussed challenge facing the RNA-LNP field near- and long-term. However, as these three LNP experts share in this Advancing RNA Live clip, they have a whole list of additional R&D and CMC priorities we must address/accomplish to improve RNA-LNPs’ efficacy in personalized and gene therapy approaches.
-
How To Manufacture LNPs On The Nova Benchtop System
4/18/2024
Walk step-by-step instructions through how you can set up the Nova Benchtop System and make your first LNPs.
-
CMC Innovations Worth Watching In The RNA-LNP Space
12/4/2024
Sanofi’s Sumit Luthra shares several of the analytical and manufacturing innovations/improvements he’s watching and waiting for that will improve our knowledge of LNP composition, structure, function, and quality.